复发难治性滤泡性淋巴瘤的治疗:哪条治疗线该用哪种方案、给哪位患者?
本文综述复发难治性滤泡性淋巴瘤治疗格局的变化。化疗长期作为治疗骨干,但靶向表观遗传调节因子、B细胞受体及其下游通路和肿瘤微环境的新型靶向、免疫调节及免疫治疗正在挑战其地位。双特异性抗体与嵌合抗原受体T细胞疗法可重定向免疫系统、增强固有抗肿瘤免疫应答。这些策略的合理联合正在复发难治环境中积极评估,并将 inevitably 前移至更早治疗线。
要点
- 化疗长期是滤泡性淋巴瘤治疗骨干,但新型靶向、免疫调节和免疫治疗正在挑战其地位。
- 双特异性抗体和嵌合抗原受体T细胞疗法可重定向免疫系统、增强固有抗肿瘤免疫应答。
- 治疗选择需综合考虑既往治疗史、治疗目标、复发时临床和生物学特征及患者个人偏好。
核心结论
- 复发难治性滤泡性淋巴瘤的治疗格局已发生转变,新型靶向、免疫调节和免疫治疗正在挑战化疗的骨干地位。
- 理解难治性和转化性疾病的意义以及复发的时机和生物学特征,对于支持现代个体化治疗策略至关重要。
研究设计与样本
- 本文为综述,聚焦复发难治性滤泡性淋巴瘤的治疗选择,讨论靶向表观遗传调节因子、B细胞受体及其下游通路、肿瘤微环境、双特异性抗体和嵌合抗原受体T细胞疗法等策略。
主要发现
- 靶向表观遗传调节因子、B细胞受体及其下游细胞内通路和滤泡性淋巴瘤肿瘤微环境的治疗策略受到关注。
- 双特异性抗体和嵌合抗原受体T细胞疗法靶向肿瘤相关抗原和宿主特异性抗原,可重定向免疫系统、增强固有抗肿瘤免疫应答。
- 这些策略的合理联合正在复发难治环境中积极评估,并将 inevitably 前移至更早治疗线。
临床怎么用
- 原文未据此给出具体推荐;作者指出,现代个体化治疗需综合考虑患者既往治疗史、治疗目标、复发时临床和生物学特征及个人偏好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances have transformed the treatment landscape for relapsed and refractory follicular lymphoma. Although chemotherapy has long served as the backbone of treatment, the availability of novel targeted, immunomodulatory, and immunotherapeutic approaches is challenging its relevance. These approaches have focused on targeting epigenetic regulators, components of the B-cell receptor or its downstream intracellular pathways and the follicular lymphoma tumor microenvironment. The recent development of bispecific antibodies and chimeric antigen receptor T-cell therapies, which target both tumor-associated and host-specific antigens, has enabled a redirection of the immune system, enhancing the innate antitumor immune response. Rational combinations of these strategies are actively being evaluated in the relapsed and refractory setting and will inevitably move forward into earlier lines of treatment. The success of these approaches has led to numerous and parallel options for patients and clinicians. The emerging challenge now lies in how best to approach each individual patient with relapsed or refractory follicular lymphoma, addressing complex decision-making that considers a patient's previous treatment history, goals of care, clinical and biological characteristics of recurrence, and personal preferences. Understanding the implications of refractory and transformed disease, as well as the timing and biology of relapse will be critical to support a more personalized treatment approach in the modern era.
引用
- Casulo C, Sehn LH. Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? Blood. 2025. PMID: 40811857. doi:10.1182/blood.2024026018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。